Donanemab and Lecanemab
Commons · Question 119738 · Tabled 10 Mar 2026 · Department of Health and Social Care · Official record
Answered 19 Mar 2026
Question
Asked by Freddie van Mierlo
To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.
Answer
Answered by Zubir Ahmed, 19 Mar 2026
The appeals against the National Institute for Health and Care Excellence (NICE) recommendations on donanemab and lecanemab for the treatment of Alzheimer’s disease were heard by NICE’s independent appeal panel in January. The next steps of the appraisal ...